In clinical trials, patients using Semaglutide have shown an average weight loss of 15-18%, while Tirzepatide has demonstrated up to 20-22% weight loss in some cases
These include: Subcutaneous injections , like Wegovy and Ozempic Oral tablets, like Rybelsus Subcutaneous semaglutide Both Wegovy and Ozempic are injected subcutaneously on a weekly basis , under the skin of the thigh, abdomen, or upper arm
While semaglutide demonstrates cardiovascular benefits in patients with established disease (as shown in the SUSTAIN-6 and SELECT trials), the additive tachycardic effect when combined with Adderall may be clinically significant in susceptible individuals, particularly those with pre-existing hypertension, arrhythmias, or structural heart disease
Semaglitude treats type 2 diabetes